Evidence map›Paper›PMID 35193434›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Development of naringenin-

Jing Yang, Yi Zhou, Yujuan Ban, Jing Mi, Ying He, Xinjuan Li, Zhengwei Liu, Keren Wang, Gaofeng Zhu, Wenmin Liu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jing YangCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Yi ZhouCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Yujuan BanState Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.
Jing MiCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Ying HeCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Xinjuan LiCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Zhengwei LiuCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Keren WangCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Gaofeng ZhuState Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.
Wenmin LiuCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Zhenghuai TanInstitute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, China.
Zhipei SangCollege of Chemistry and Pharmaceutical Engineering, Nanyang Normal University, Nanyang, China.
Nanyang Normal University · CNGuiyang Medical University · CNSichuan Academy of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a series of naringenin-

Indexed as

AcetylcholinesteraseAlzheimer DiseaseAminesAmyloid beta-PeptidesAnimalsAntioxidantsBlood-Brain BarrierButyrylcholinesteraseCell LineCell SurvivalCholinesterase InhibitorsDose-Response Relationship, DrugDrug DevelopmentFlavanonesHumansMiceAcetylcholinesteraseAminesAmyloid beta-PeptidesAntioxidantsButyrylcholinesteraseCholinesterase InhibitorsFlavanonesnaringeninNeuroprotective AgentsProtein AggregatesAlzheimer’s diseasemultifunctional agentsnaringenin-O-alkylamine derivativesscopolamine-induced mice memory impairment

Identifiers

PMID35193434
PMCPMC8881077
OpenAlexW4213424487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.